Your browser doesn't support javascript.
loading
New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine.
Bury, Dagmar; Alexander-White, Camilla; Clewell, Harvey J; Cronin, Mark; Desprez, Bertrand; Detroyer, Ann; Efremenko, Alina; Firman, James; Hack, Eric; Hewitt, Nicola J; Kenna, Gerry; Klaric, Martina; Lester, Cathy; Mahony, Catherine; Ouedraogo, Gladys; Paini, Alicia; Schepky, Andreas.
Afiliação
  • Bury D; L'Oréal, Research & Innovation, 9 Rue Pierre Dreyfus, 92110, Clichy, France. Electronic address: dagmar.bury@rd.loreal.com.
  • Alexander-White C; MKTox & Co Ltd, 36 Fairford Crescent, Downhead Park, Milton Keynes, Buckinghamshire, MK15 9AQ, UK.
  • Clewell HJ; Ramboll Health Sciences, 3107 Armand Street, Monroe, LA, 71201, USA.
  • Cronin M; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK.
  • Desprez B; Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.
  • Detroyer A; L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France.
  • Efremenko A; ScitoVation, Research Triangle Park, Durham, NC, USA.
  • Firman J; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 AF, UK.
  • Hack E; ScitoVation, Research Triangle Park, Durham, NC, USA.
  • Hewitt NJ; The Procter & Gamble Co., Cincinnati, OH, USA.
  • Kenna G; Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.
  • Klaric M; Cosmetics Europe, 40 Avenue Hermann-Debroux, 1160, Brussels, Belgium.
  • Lester C; The Procter & Gamble Co., Cincinnati, OH, USA.
  • Mahony C; Procter & Gamble Technical Centres Ltd, Reading, RG2 0RX, UK.
  • Ouedraogo G; L'Oréal, Research & Innovation, 1 Avenue Eugène Schueller, Aulnay-sous-Bois, France.
  • Paini A; European Commission Joint Research Centre, Ispra, Italy.
  • Schepky A; Beiersdorf, Unnastrasse 48, 20253, Hamburg, Germany.
Regul Toxicol Pharmacol ; 123: 104931, 2021 Jul.
Article em En | MEDLINE | ID: mdl-33905778
This case study on the model substance caffeine demonstrates the viability of a 10-step read-across (RAX) framework in practice. New approach methodologies (NAM), including RAX and physiologically-based kinetic (PBK) modelling were used to assess the consumer safety of caffeine. Appropriate animal systemic toxicity data were used from the most relevant RAX analogue while assuming that no suitable animal toxicity data were available for caffeine. Based on structural similarities, three primary metabolites of the target chemical caffeine (theophylline, theobromine and paraxanthine) were selected as its most relevant analogues, to estimate a point of departure in order to support a next generation risk assessment (NGRA). On the basis of the pivotal mode of action (MOA) of caffeine and other methylxanthines, theophylline appeared to be the most potent and suitable analogue. A worst-case aggregate exposure assessment determined consumer exposure to caffeine from different sources, such as cosmetics and food/drinks. Using a PBK model to estimate human blood concentrations following exposure to caffeine, an acceptable Margin of Internal Exposure (MOIE) of 27-fold was derived on the basis of a RAX using theophylline animal data, which suggests that the NGRA approach for caffeine is sufficiently conservative to protect human health.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cafeína / Testes de Toxicidade / Cosméticos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cafeína / Testes de Toxicidade / Cosméticos Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Ano de publicação: 2021 Tipo de documento: Article
...